The full datasheet can be viewed on Wegovy is administered by a once weekly subcutaneous injection underneath the skin
Injection site reactions are among the most frequently reported adverse effects associated with subcutaneous medicines, including those in the GLP-1 receptor agonist class
Retatrutide for the treatment of obesity, obstructive sleep apnea and related conditions (phase 3 basket trial)
Personalized Treatment Recommendations Based on your evaluation, we develop a customized treatment plan that may include: Nutrition guidance Lifestyle modifications Prescription medications GLP-1 therapy Follow-up visits and monitoring Ongoing Support and Accountability Successful long-term weight loss requires consistency and support
Weghuber D, Barrett T, Barrientos-Perez M, et al
The current ASA guidelines are based on expert consensus rather than high-quality clinical evidence, and may not adequately address the perioperative risks posed by these medications